Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma By Ogkologos - March 16, 2026 97 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ZSAB-neoGOLP study Source RELATED ARTICLESMORE FROM AUTHOR Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian Patient Guide in Bladder Cancer Now Available Also in French MOST POPULAR Preguntas frecuentes sobre el COVID-19 y el cáncer: Respuestas para pacientes... June 25, 2020 Jennifer Garner Shared A Video Of Her Mammogram Appointment October 21, 2019 Failed Alzheimer’s Drug Might Boost CAR T-Cell Therapy for Multiple Myeloma October 25, 2019 Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type... February 27, 2020 Load more HOT NEWS Our new strategy to make discoveries, drive progress, and bring hope Mom Diagnosed With Breast Cancer Adopts Healthy Lifestyle To Reinvent Her... What People With Breast Cancer and Survivors Should Know About Exercising... Exercising Safely During Breast Cancer Treatment: What to Know
